Whitney Lem

Angela, on behalf of Whitney Lem, asked for updates on payer conversations for the HO launch, whether most patients would initially be on a free drug program, and color on the gross-to-net around launch.

Answer

David Meeker, Chairman, CEO and President, Rhythm Pharmaceuticals, clarified that clinical trial patients would remain on drug, but there would not be a specific early access program. Jennifer Lee, EVP, Head of North America, Rhythm Pharmaceuticals, expressed positivity about payer feedback and market research. She explained that reimbursement processes would be similar to BBS, where access was gained even before formal policies were in place. David Meeker added that the gross-to-net difference for HO is hard to predict but primarily driven by the Medicare/commercial mix, as rebates are not a significant factor.

Angela, on behalf of Whitney Lem, inquired about updates on payer conversations for the HO launch, whether most patients would be on a free drug program until policies finalize, and color on the gross-to-net around launch.

Answer

David Meeker, Chairman, CEO and President, clarified that there would be no specific early access program for new HO patients, but clinical trial patients would remain on drug until access is secured. Jennifer Lee, EVP, Head of North America, expressed positive feedback from payer discussions and market research, expecting a similar reimbursement process to BBS where access was gained even without formal policies, thus not requiring a wait for policy finalization.